NovoCure Limited
NVCR
$17.24
$0.392.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -107.28% | 62.84% | -21.92% | -20.27% | 11.46% |
| Total Depreciation and Amortization | 24.03% | 55.56% | 49.02% | 20.50% | 18.12% |
| Total Amortization of Deferred Charges | -- | 0.19% | -- | -- | -- |
| Total Other Non-Cash Items | 168.67% | -72.69% | 6.28% | 7.77% | -26.64% |
| Change in Net Operating Assets | 71.41% | -431.62% | 94.04% | -296.54% | -2.80% |
| Cash from Operations | 62.10% | -421.70% | 98.28% | -826.51% | -12.96% |
| Capital Expenditure | 51.45% | 45.25% | 47.07% | 52.07% | 9.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 211.65% | 2,671.57% | 269.28% | 111.42% | -98.40% |
| Cash from Investing | 219.70% | 1,614.23% | 600.83% | 109.61% | -102.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -92.57% | -40.52% | 438.00% | -27.84% | 2,363.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -103.16% | -20,937.77% | 100,417.00% | -97.27% | 2,363.38% |
| Foreign Exchange rate Adjustments | -157.27% | 40.63% | -125.29% | 444.16% | 505.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.45% | -944.14% | 827.47% | 107.86% | -117.07% |